R.G. Langley, K. Papp, A.B. Gottlieb, G.G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze and B. Strober Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis Journal of the European Academy of Dermatology and Venereology 27
Article first published online: 16 NOV 2012 | DOI: 10.1111/j.1468-3083.2012.04705.x
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.